Skip to main content
Equibles
BRGX logo

BRGX · Bioregenx, Inc.

Track BRGX — free

Use BRGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BRGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 +0.00 (+55.56%) At close · Sep 16
Rebalance outlook locked
Going-concern doubt — flagged May 20, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(26,415), generated cash from operations of $26,629 and had a stockholder's deficit of $4,533,316 as of that date. At March 31, 2026, the Company had cash on hand in the amount of $45,806. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed May 20, 2026
Market Cap
$4.37M
Shares
971.58M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.01 Open$0.01 Day$0.01–0.01 52W close$0.00–0.03 Avg vol 30d64K Short int10K · 0.0% float · 1.0d Short vol36% DataJan 2020–Sep 2026 Filing10-Q · May 20

Up next

Latest filing: 10-Q
filed May 20, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.77M
Trailing 12 months
Net income (TTM)
−$1.30M
Trailing 12 months
Revenue growth YoY
-17.3%
Year over year
Operating margin
-62.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-36.4%
Trailing year
Short interest
—
Latest settlement
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.52
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −18%
below
RSI (14) 49
neutral
MACD trend Negative
52-week position 12%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −46%
trailing
YTD return −46%
this year
Relative strength −61%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -84.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Strong
Revenue growth −21%
Y/Y
Gross margin 81%
expanding
EPS growth +100%
Y/Y
Free cash flow $29.9K
Balance sheet $1.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 473%
annualized · 1-yr
Max drawdown −85%
past year
ATR 18.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
12% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -84.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 12% Range high $0
vs 200-day avg -44% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BRGX
Bioregenx, Inc.
this stock
$4.37M -45.7% -20.8% — 0.0%
VEEV
Veeva Systems Inc
 $43.69B +18.2% +28.1% 44.2 3.0%
PMDIY
Pro Medicus Ltd./ADR
 $12.54B -28.9% — — 0.0%
TEM
Tempus AI, Inc.
 $11.99B +36.1% +83.4% — 16.3%
BTSG
BrightSpring Health Services, Inc.
 $11.73B +51.1% +28.2% 35.9 5.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Falling
Shares short
10.0K
Days to cover
1.0d
Change
-56.0K sh
View
Short Volume
Short vol %
36%
As of
Sep 8, 2026
Short Total
View
Fails to Deliver
FTD shares
31.1K
Value
$311
As of
Dec 12, 2025
View
Off-Exchange
Off-exchange %
100.0%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.9M
Net income (FY)
$-1.5M
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
10-Q
Filed
May 20, 2026
This year
2
View

Performance

5D 20D 120D MTD YTD
BRGX -12.5% -15.7% -46.2% -12.5% -45.7%
SPY -1.1% -1.8% +14.8% -1.7% +10.6%
vs SPY -11.4% -13.9% -61.0% -10.8% -56.3%
Key facts CIK 1593184 Visit website